Acute Urticaria That Did Not Achieve Complete Control on Standard-Dose Antihistamine

In some patients with acute urticaria, a regular daily course of a standard-dose modern 2nd-generation H1-antihistamine does not deliver full symptom clearance. This protocol defines the structured next step when first-line therapy falls short of the target.

Previous Treatment — Failure Condition

First-line management consisted of a standard-dose modern 2nd-generation H1-antihistamine taken regularly on a daily basis. The required outcome was complete symptom control — consistent absence of wheals and pruritus (UAS = 0). Escalation to this protocol is indicated when that target is not consistently reached.

Next-Step Approach (partial overview)

When standard dosing proves insufficient, the management strategy involves a specific adjustment to the antihistamine regimen already in use. The full details — including which adjustments apply and the options available — are laid out in the complete protocol.

Treatment Goal

Complete symptom control — consistent absence of wheals and pruritus, targeting a Urticaria Activity Score of zero (UAS = 0).

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/all.70210

Increase 2nd generation AH dose (up to 4x)

Studies support the use of up to fourfold standard-dosed bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, mizolastine, and rupatadine.

We recommend aiming at complete symptom control in urticaria, considering as much as possible the safety and the quality of life of each individual patient.

View source ↗